Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.

These findings strongly point at AU-SAR-M1 as a promising radiotherapeutic candidate when labeled with Lu-177, or other medically appealing therapeutic radiometals, especially when combined with in situ NEP-inhibition. To this goal further investigations are currently pursued.